ESSA is a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer. ESSA’s lead clinical candidate, EPI-7386, represents a new approach to disrupting androgen receptor signaling pathway, the primary driver of prostate cancer growth.
ESSA’s investigational therapies are designed to disrupt the androgen receptor (AR) signaling pathway, the primary pathway that drives prostate cancer growth, and prevent AR activation through selective binding to the N-terminal domain, a region of the AR that is not currently targeted by other therapies.
Phase 1 trial of EPI-7386 in patients with castration-resistant prostate cancer (CRPC).
Russell Pachynski, MD, Associate Professor of Medicine, Washington University School of Medicine in St. Louis, discusses ESSA’s Phase 1 EPI-7386 monotherapy clinical trial with UroToday at the American Society for Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2023.
Phase 1/2 trial of EPI-7386 with enzalutamide in patients with metastatic CRPC (mCRPC).
Andrew Laccetti, MD, MS, Medical Oncologist, Memorial Sloan Kettering Cancer Center, discusses ESSA’s Phase 1/2 EPI-7386 + enzalutamide combination clinical trial with UroToday at the American Society for Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2023.
AR is activated by androgen binding to the LBD which induces the dimerization and nuclear translocation of the AR. Activated AR then regulates the expression of genes involved in prostate cancer progression.
Current AR-targeted therapies work directly or indirectly through the LBD of the AR
Anitens target the NTD of the AR and can inhibit AR transcriptional activity
Anitens are active against AR forms missing the LBD and therefore, can bypass many resistance mechanisms to current AR-targeted therapies.
